Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06801626 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Novel Strategies for Reducing Burn Scar Itch

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2026 → Dec 31, 2027
See other at-risk trials from The University of Texas Medical Branch, Galveston

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 31, 2026 to Dec 31, 2027
    • Study completion pushed from Nov 1, 2027 to Nov 1, 2028
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 5 of 6 entries
  2. Interventions: Famotidine and 4% topical cromolyn sodium (Combination Product) to Famotidine and 4% topical cromolyn sodium (Combination Product), Placebo (Other)v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 2025 to Mar 1, 2025
    • Secondary endpoints: details revised at 2 of 6 entries
    • Study description expanded, about 1 word
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to see whether using diphenhydramine (Benadryl), famotidine (Pepcid), and cromolyn sodium will decrease burn scar itch.
Trial Details
NCT Number NCT06801626
Lead Sponsor The University of Texas Medical Branch, Galveston
Collaborators: University of Texas
Conditions
(from sponsor)		 Burn Scar, Itch Scarring, Wound
Related terms Burns, Pruritus, Wounds and Injuries
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov